Indexado em
  • Banco de Dados de Periódicos Acadêmicos
  • Abra o Portão J
  • Genamics JournalSeek
  • JournalTOCs
  • Infraestrutura Nacional de Conhecimento da China (CNKI)
  • Scimago
  • Diretório de Periódicos de Ulrich
  • RefSeek
  • Universidade de Hamdard
  • EBSCO AZ
  • OCLC- WorldCat
  • publons
  • MIAR
  • Comissão de Bolsas Universitárias
  • Fundação de Genebra para Educação e Pesquisa Médica
  • Euro Pub
  • Google Scholar
Compartilhe esta página

Abstrato

Measles and Rubella Vaccination Campaign 2019: An Update of Adverse Events

Roop Sharma, Ajay Gaur

Objectives: To study the various adverse reactions caused post measles and rubella vaccination done during MR vaccine campaign.

Materials and methods: Prospective, observational study done in a government tertiary care PICU. Children aged between 9 month to 15 years, who presented with adverse effects (severe enough to warrant admission) within 7 days of MR vaccine administration.

Results: Most common presenting complaint was fever (44.8%), followed by vomiting (34.5%), abdominal pain and dizziness (31%). Abnormal body movements were noted in 2 children (6.8%) on first day and in 1 child on fifth day of vaccine administration. 2 children (6.8%) presented with generalised macular rashes all over the body on 4th day after vaccination. Altered sensorium on same day of vaccine administration was the presenting symptom of 1 child. All children improved gradually and were discharged after few days with no mortality or long term morbidity. Investigations were done according to the protocol of the unit, nothing came significant to be reported. Neither of the children had positive blood culture.

Conclusion: MR vaccination programs are scientifically sound, highly recommended and proven effective globally. Causality assessment of adverse events is still an evolving science and despite taking all the measures, and adopting all the available scientific methods, sometimes it is not possible to incontrovertibly prove the causal association of an event with a vaccine. Much more advancement in this area is needed.